Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DAWN Day One Biopharmaceuticals	$7.51 -1.1%	$6.72	$5.64 ▼ $16.76	$769.26M	-1.26	2.08 million shs	893,899 shs
DNA Ginkgo Bioworks	$12.71 +4.4%	$11.93	$5.00 ▼ $16.85	$750.06M	1.5	1.59 million shs	2.03 million shs
NRIX Nurix Therapeutics	$9.34 -0.7%	$11.20	$8.18 ▼ $29.56	$714.03M	2.14	610,933 shs	1.83 million shs
VYGR Voyager Therapeutics	$3.36 -1.2%	$3.29	$2.64 ▼ $8.27	$186.38M	0.9	765,882 shs	203,262 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DAWN Day One Biopharmaceuticals	0.00%	+4.31%	+11.92%	+17.53%	-46.43%
DNA Ginkgo Bioworks	0.00%	+1.62%	-2.99%	+82.63%	+79.03%
NRIX Nurix Therapeutics	0.00%	-7.89%	-17.05%	-12.05%	-62.77%
VYGR Voyager Therapeutics	0.00%	-2.04%	+5.33%	+23.53%	-48.23%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
DAWN Day One Biopharmaceuticals	2.4632 of 5 stars	3.6	2.0	0.0	3.0	2.5	0.0
DNA Ginkgo Bioworks	1.0341 of 5 stars	1.2	3.0	0.0	2.6	2.5	0.6
NRIX Nurix Therapeutics	2.7278 of 5 stars	4.4	2.0	0.0	3.0	0.8	0.0
VYGR Voyager Therapeutics	3.6171 of 5 stars	3.6	1.0	4.6	1.6	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DAWN Day One Biopharmaceuticals	3.13	Buy	$25.29	236.69% Upside
DNA Ginkgo Bioworks	2.33	Hold	$9.50	-25.26% Downside
NRIX Nurix Therapeutics	2.88	Moderate Buy	$28.87	209.06% Upside
VYGR Voyager Therapeutics	3.13	Buy	$13.25	294.26% Upside

Current Analyst Ratings Breakdown

Latest VYGR, NRIX, DNA, and DAWN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/26/2025	NRIX Nurix Therapeutics	Baird R W Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
8/25/2025	DNA Ginkgo Bioworks	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sell ➝ Sell	$6.00 ➝ $9.00
8/18/2025	DAWN Day One Biopharmaceuticals	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight ➝ Overweight	$25.00
8/8/2025	DNA Ginkgo Bioworks	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
8/7/2025	VYGR Voyager Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$9.00 ➝ $8.00
8/6/2025	DAWN Day One Biopharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$18.00 ➝ $16.00
8/6/2025	DAWN Day One Biopharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$36.00 ➝ $25.00
7/31/2025	NRIX Nurix Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$32.00 ➝ $30.00
7/15/2025	NRIX Nurix Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Equal Weight ➝ Equal Weight	$17.00 ➝ $16.00
7/14/2025	NRIX Nurix Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$36.00 ➝ $34.00
7/10/2025	NRIX Nurix Therapeutics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$30.00 ➝ $26.00

(Data available from 8/31/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DAWN Day One Biopharmaceuticals	$131.16M	5.86	N/A	N/A	$4.50 per share	1.67
DNA Ginkgo Bioworks	$227.04M	3.31	N/A	N/A	$10.35 per share	1.23
NRIX Nurix Therapeutics	$54.55M	13.09	N/A	N/A	$7.44 per share	1.26
VYGR Voyager Therapeutics	$42.58M	4.38	N/A	N/A	$4.40 per share	0.76

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DAWN Day One Biopharmaceuticals	-$95.50M	-$0.95	N/A	N/A	N/A	-50.63%	-19.01%	-16.99%	10/29/2025 (Estimated)
DNA Ginkgo Bioworks	-$547.03M	-$5.86	N/A	N/A	N/A	-136.56%	-43.25%	-22.29%	11/11/2025 (Estimated)
NRIX Nurix Therapeutics	-$193.57M	-$2.61	N/A	N/A	N/A	-234.57%	-45.26%	-34.71%	10/10/2025 (Estimated)
VYGR Voyager Therapeutics	-$65M	-$1.85	N/A	N/A	N/A	-253.49%	-37.65%	-28.89%	11/11/2025 (Estimated)

Latest VYGR, NRIX, DNA, and DAWN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	DNA Ginkgo Bioworks	-$1.44	-$1.10	+$0.34	-$1.10	$41.60 million	$49.60 million
8/6/2025	Q2 2025	VYGR Voyager Therapeutics	-$0.48	-$0.57	-$0.09	-$0.57	$9.50 million	$5.20 million
8/5/2025	Q2 2025	DAWN Day One Biopharmaceuticals	-$0.35	-$0.29	+$0.06	-$0.29	$35.55 million	$33.91 million
7/9/2025	Q2 2025	NRIX Nurix Therapeutics	-$0.79	-$0.52	+$0.27	-$0.52	$16.26 million	$44.06 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
DAWN Day One Biopharmaceuticals	N/A	N/A	N/A	N/A	N/A
DNA Ginkgo Bioworks	N/A	N/A	N/A	N/A	N/A
NRIX Nurix Therapeutics	N/A	N/A	N/A	N/A	N/A
VYGR Voyager Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DAWN Day One Biopharmaceuticals	N/A	9.65	9.53
DNA Ginkgo Bioworks	N/A	5.41	5.41
NRIX Nurix Therapeutics	N/A	6.82	6.82
VYGR Voyager Therapeutics	N/A	5.43	5.43

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DAWN Day One Biopharmaceuticals	87.95%
DNA Ginkgo Bioworks	78.63%
NRIX Nurix Therapeutics	N/A
VYGR Voyager Therapeutics	48.03%

Insider Ownership

Company	Insider Ownership
DAWN Day One Biopharmaceuticals	6.20%
DNA Ginkgo Bioworks	9.72%
NRIX Nurix Therapeutics	7.40%
VYGR Voyager Therapeutics	6.39%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DAWN Day One Biopharmaceuticals	60	102.43 million	96.08 million	Optionable
DNA Ginkgo Bioworks	640	59.20 million	53.45 million	Optionable
NRIX Nurix Therapeutics	300	76.45 million	70.79 million	Optionable
VYGR Voyager Therapeutics	100	55.47 million	51.93 million	Optionable

VYGR, NRIX, DNA, and DAWN Headlines

Recent News About These Companies

Voyager Therapeutics, Inc. (NASDAQ:VYGR) Receives $13.25 Average Price Target from Analysts

August 27, 2025 | americanbankingnews.com

Voyager to Present at Upcoming Investor Conferences

August 26, 2025 | globenewswire.com

Voyager Therapeutics, Inc. (NASDAQ:VYGR) Receives Consensus Recommendation of "Buy" from Analysts

August 26, 2025 | marketbeat.com

Voyager Therapeutics Extends Cash Runway to 2028

August 13, 2025 | msn.com

Truist Financial Keeps Their Buy Rating on Voyager Therapeutics (VYGR)

August 11, 2025 | theglobeandmail.com

Voyager Therapeutics (VYGR) Receives a Buy from Oppenheimer

August 11, 2025 | theglobeandmail.com

Equities Analysts Offer Predictions for VYGR Q3 Earnings

August 11, 2025 | marketbeat.com

Voyager Therapeutics (NASDAQ:VYGR) Releases Earnings Results, Misses Estimates By $0.09 EPS

August 10, 2025 | marketbeat.com

Voyager Therapeutics (VYGR) Receives a Buy from Canaccord Genuity

August 9, 2025 | theglobeandmail.com

Voyager Therapeutics (NASDAQ:VYGR) Price Target Lowered to $8.00 at Wedbush

August 8, 2025 | marketbeat.com

Voyager Therapeutics (VYGR) Reports Q2 Loss, Lags Revenue Estimates

August 6, 2025 | zacks.com

Voyager Reports Second Quarter 2025 Financial and Operating Results

August 6, 2025 | globenewswire.com

Voyager 1 and 2: From Earth to Interstellar Space: The Final Frontier Awaits

July 21, 2025 | msn.com

Read the NASA ‘Voyager Declaration’ Letter of Dissent

July 21, 2025 | nytimes.com

Mascarene Partners Acquires Voyager Trucking

July 18, 2025 | finance.yahoo.com

Mascarene buys US waste services company Voyager Trucking

July 18, 2025 | realassets.ipe.comR

Voyager Therapeutics adds new gene therapy to Alzheimer’s program

July 18, 2025 | bioworld.comB

Mascarene to acquire waste services transport firm Voyager Trucking Corporation

July 18, 2025 | pehub.com

Looking Beyond Voyager 1 And 2

July 17, 2025 | msn.com

Robert Beltran on Star Trek: I “Risked being fired” Because I Didn’t Like What Was Happening in the Last 3 Years of Voyager

July 16, 2025 | fandomwire.comF

Uranus Heat Readings Contradict 40-Year-Old Voyager 2 Results

July 16, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

VYGR, NRIX, DNA, and DAWN Company Descriptions

Day One Biopharmaceuticals NASDAQ:DAWN

$7.51 -0.08 (-1.05%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$7.50 0.00 (-0.07%)

As of 08/29/2025 04:20 PM Eastern

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.

Ginkgo Bioworks NYSE:DNA

$12.71 +0.54 (+4.45%)

Closing price 08/29/2025 03:59 PM Eastern

Extended Trading

$12.52 -0.20 (-1.54%)

As of 08/29/2025 07:59 PM Eastern

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Nurix Therapeutics NASDAQ:NRIX

$9.34 -0.07 (-0.74%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$9.34 0.00 (0.00%)

As of 08/29/2025 05:38 PM Eastern

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc., Sanofi S.A., and Seagen Inc. co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.

Voyager Therapeutics NASDAQ:VYGR

$3.36 -0.04 (-1.18%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$3.42 +0.06 (+1.79%)

As of 08/29/2025 04:30 PM Eastern

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time